# Nuclide record prostate (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/prostate/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "prostate" ;
  schema:name "Prostate cancer"@en ;
  schema:description "Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."@en ;
  schema:url <https://nuclide.cc/indications/prostate/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q181257> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  nuclide:tag "gu", "spike" ;
  nuclide:related <https://nuclide.cc/roadmaps/radiopharma-roadmap/>, <https://nuclide.cc/pairings/psma-pet-to-rlt/>, <https://nuclide.cc/pairings/beta-then-alpha/>, <https://nuclide.cc/collections/src-urotoday/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/ra-223/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/parp/>, <https://nuclide.cc/targets/b7h3/>, <https://nuclide.cc/targets/dll3/>, <https://nuclide.cc/targets/steap1/>, <https://nuclide.cc/targets/klk2/>, <https://nuclide.cc/targets/grpr/> ;
  nuclide:drugs <https://nuclide.cc/drugs/samarium-153-lexidronam/> ;
  nuclide:companies <https://nuclide.cc/companies/futurechem/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/bayer/>, <https://nuclide.cc/companies/pfizer/>, <https://nuclide.cc/companies/johnson-johnson/>, <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/lantheus/>, <https://nuclide.cc/companies/telix/>, <https://nuclide.cc/companies/curium/> ;
  nuclide:institutions <https://nuclide.cc/institutions/royal-marsden/>, <https://nuclide.cc/institutions/peter-mac/>, <https://nuclide.cc/institutions/ucla-jonsson/>, <https://nuclide.cc/institutions/johns-hopkins/> ;
  nuclide:pathways <https://nuclide.cc/pathways/prostate-cancer-signalling/> ;
  nuclide:terms <https://nuclide.cc/terms/biochemical-recurrence/>, <https://nuclide.cc/terms/psa50/>, <https://nuclide.cc/terms/theranostics/>, <https://nuclide.cc/terms/oligometastatic/>, <https://nuclide.cc/terms/crossover/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06855277/>, <https://nuclide.cc/trials/nct06780670/>, <https://nuclide.cc/trials/mcrpc/>, <https://nuclide.cc/trials/nct07311694/>, <https://nuclide.cc/trials/nct07615101/>, <https://nuclide.cc/trials/nct07649122/>, <https://nuclide.cc/trials/nct05381103/>, <https://nuclide.cc/trials/pop-rt/>, <https://nuclide.cc/trials/nct05939414/>, <https://nuclide.cc/trials/nct06520345/>, <https://nuclide.cc/trials/nct07052214/>, <https://nuclide.cc/trials/nct07611110/>, <https://nuclide.cc/trials/nct04557059/>, <https://nuclide.cc/trials/nct06235151/>, <https://nuclide.cc/trials/nct06754085/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/aaa817/>, <https://nuclide.cc/drugs/jnj-87189401/>, <https://nuclide.cc/drugs/hrs-4357/>, <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/trials/alphabreak/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/trials/eclipse-psma/>, <https://nuclide.cc/ideas/idea-psma-pet-guided-mdt/>, <https://nuclide.cc/ideas/idea-alpha-first-mhspc/>, <https://nuclide.cc/targets/grpr/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/olaparib/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/trials/stampede/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/terms/biochemical-recurrence/>, <https://nuclide.cc/trials/embark/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/ideas/idea-psma-pet-guided-mdt/>, <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/psmaddition/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/drugs/olaparib/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/pembrolizumab/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/drugs/cabazitaxel/>, <https://nuclide.cc/drugs/radium-223/>, <https://nuclide.cc/trials/alsympca/>, <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/trials/alphabreak/> .